Weekly Recap: Intra-Cellular $14.6B deal and JNJ’s Carvykti 50% remissions

Johnson & Johnson (NYSE:JNJ) is integrating its $14.6B Intra-Cellular Therapies buy while weighing Caplyta's expanded label after positive trials, reporting strong Carvykti long-term remission and survival data, completing a second pivotal Caplyta Phase 3 study, and announcing Tremfya success in ax…